{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=B+complex&page=4", "query": { "intervention": "B complex", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 911, "total_pages": 92, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=B+complex&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=B+complex&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-18T09:31:54.753Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01159119", "title": "A Study of EUR-1066 in Subjects With Chronic Pancreatitis, Exocrine Pancreatic Insufficiency and Chronic Abdominal Pain", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Pancreatitis" ], "interventions": [ { "name": "EUR-1066-A", "type": "DRUG" }, { "name": "Zenpep", "type": "DRUG" }, { "name": "EUR-1066-B", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Forest Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2010-08-02", "completion_date": "2011-07-01", "has_results": false, "last_update_posted_date": "2020-01-18", "last_synced_at": "2026-10-18T09:31:54.753Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01159119" }, { "nct_id": "NCT01413022", "title": "FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Neoplasms" ], "interventions": [ { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "PF-04136309", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2012-04", "completion_date": "2016-09", "has_results": false, "last_update_posted_date": "2016-09-19", "last_synced_at": "2026-10-18T09:31:54.753Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01413022" }, { "nct_id": "NCT01484522", "title": "Laboratory Study of Licensed H1N1 Influenza Vaccines in HIV-1 Perinatally Infected Children and Youth", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV-1 Infection", "H1N1", "Influenza", "Flu" ], "interventions": [ { "name": "FluMist", "type": "BIOLOGICAL" }, { "name": "Fluvirin", "type": "BIOLOGICAL" }, { "name": "Fluzone", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "International Maternal Pediatric Adolescent AIDS Clinical Trials Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "25 Years", "sex": "ALL", "summary": "6 Months to 25 Years" }, "enrollment_count": 149, "start_date": "2009-10", "completion_date": "2010-09", "has_results": false, "last_update_posted_date": "2011-12-02", "last_synced_at": "2026-10-18T09:31:54.753Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01484522" }, { "nct_id": "NCT05533775", "title": "A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Mature B-Cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Glofitamab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "30 Years", "sex": "ALL", "summary": "6 Months to 30 Years" }, "enrollment_count": 65, "start_date": "2022-11-16", "completion_date": "2032-11-30", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-18T09:31:54.753Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Oakland, California • Roseville, California + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Oakland", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Roseville", "state": "California" }, { "city": "Santa Clara", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05533775" }, { "nct_id": "NCT06799494", "title": "HPV Vaccine Reduced Dose", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HPV" ], "interventions": [ { "name": "Gardasil-9", "type": "BIOLOGICAL" }, { "name": "Lidocaine injection", "type": "DRUG" }, { "name": "Lorazepam", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 100, "start_date": "2025-08-06", "completion_date": "2028-09", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-10-18T09:31:54.753Z", "location_count": 1, "location_summary": "Decatur, Georgia", "locations": [ { "city": "Decatur", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06799494" }, { "nct_id": "NCT00003398", "title": "Bone Marrow Transplantation in Treating Patients With Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Anemia", "Graft Versus Host Disease", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "bone marrow ablation with stem cell support", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "50 Years", "sex": "ALL", "summary": "Up to 50 Years" }, "enrollment_count": 45, "start_date": "1998-09", "completion_date": "2000-05", "has_results": false, "last_update_posted_date": "2019-10-17", "last_synced_at": "2026-10-18T09:31:54.753Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003398" }, { "nct_id": "NCT01282762", "title": "Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Kidney Disease" ], "interventions": [ { "name": "HEPLISAV", "type": "BIOLOGICAL" }, { "name": "Engerix-B", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Dynavax Technologies Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 147, "start_date": "2010-12", "completion_date": "2013-08", "has_results": false, "last_update_posted_date": "2019-03-20", "last_synced_at": "2026-10-18T09:31:54.753Z", "location_count": 1, "location_summary": "Norfolk, Virginia", "locations": [ { "city": "Norfolk", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01282762" }, { "nct_id": "NCT00081809", "title": "A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Follicular", "Lymphoma, Small Lymphocytic" ], "interventions": [ { "name": "autologous human tumor-derived HSPPC-96", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Agenus Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 35, "start_date": "2000-03", "completion_date": "2005-06", "has_results": false, "last_update_posted_date": "2023-09-28", "last_synced_at": "2026-10-18T09:31:54.753Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00081809" }, { "nct_id": "NCT01881230", "title": "Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Breast Tumor", "Breast Cancer", "Cancer of the Breast", "Estrogen Receptor- Negative Breast Cancer", "HER2- Negative Breast Cancer", "Progesterone Receptor- Negative Breast Cancer", "Recurrent Breast Cancer", "Stage IV Breast Cancer", "Triple-negative Breast Cancer", "Triple-negative Metastatic Breast Cancer", "Metastatic Breast Cancer" ], "interventions": [ { "name": "nab-Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 191, "start_date": "2013-09-26", "completion_date": "2016-10-28", "has_results": true, "last_update_posted_date": "2019-02-21", "last_synced_at": "2026-10-18T09:31:54.753Z", "location_count": 64, "location_summary": "Chandler, Arizona • Glendale, Arizona • Scottsdale, Arizona + 57 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01881230" }, { "nct_id": "NCT02472392", "title": "Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "EWINGS SARCOMA" ], "interventions": [ { "name": "Rabbit anti-thymocyte globulin", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Louisville", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 10, "start_date": "2013-04", "completion_date": "2016-12", "has_results": false, "last_update_posted_date": "2017-05-09", "last_synced_at": "2026-10-18T09:31:54.753Z", "location_count": 1, "location_summary": "Louisville, Kentucky", "locations": [ { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT02472392" } ] }